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Background
Transcatheter aortic valve implantation (TAVI) has
become a method of choice in repair of valvular aortic
stenosis, especially in group of patients with high surgi-
cal risk.
Aim
The objective was to evaluate the immediate and mid-
term results of applying TAVI in aortic valve surgery.
Methods
80 patients with a median age of 78 ± 5.2 years were
included. All patients had severe aortic stenosis. According
to the echo an average gradient of systolic pressure on the
aortic valve was >20% by EuroSCORE and > 10% by STS.
We have implanted Edwards Sapiens/Sapiens XT or Med-
tronic CoreValve bioprostheses. In 58 cases implantation
was performed through transfemoral access (including 30
Edwards Sapien cases) and in 17 cases- transapical access
was used due to vascular abnormalities. In the rest 5
patients we used direct transaortic (4 cases) and in 1 case -
transsubclavian approach.
Results
Intraoperative mortality was 1.25%: 1 patient (women)
died with symptoms of acute heart failure. Total 30 days
mortality rate was 5%: 2 patients died within 7 days
after TAVI - IM and other 2 patients developed cardio-
genic shock. Incidence of non-fatal stroke was 2.5%. In
2 patients the procedure of hemodialysis needed to be
performed because of acute contrast-induced renal
injury. Other patients had no significant complications.
The AMPG after Edwards Sapien and Medtronic Core-
Valve implantations were 10,9 ± 3,5 and 14,3 ± 5,4 mm
Hg respectively. The incidence of paravalvular leak of 2
degree had a tendency to be higher in CoreValve than
in Edwards Sapien subgroup (15% vs. 5%). Nevertheless,
by the end of 1-year follow-up only 2 patients had resi-
dual aortic regurgitation >2 degree (CoreValve). In 5
patients after CoreValve implantation (25%) - need of
permanent pacemaker. The overall mortality rate by the
end of 1-year was 12% with no procedure-related deaths.
Conclusion
TAVI can be considered as a real alternative to tradi-
tional aortic valve replacement in high-risk patients.
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